Partial bilateral aplasia of the mullerian ducts

Summary

Partial bilateral aplasia of the mullerian ducts (MONDO:0015830) is a disease. A subtype of mullerian aplasia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	partial bilateral aplasia of the mullerian ducts
Mondo ID	MONDO:0015830
Orphanet	180068
UMLS	C5679589
MedGen	1843187
GARD	0020172
Is cancer (heuristic)	no

Also known as: incomplete bilateral aplasia of the Mullerian ducts · incomplete bilateral aplasia of the Müllerian ducts

Disease family

This is a subtype of mullerian aplasia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › reproductive system disorder › female reproductive system disorder › mullerian aplasia › partial bilateral aplasia of the mullerian ducts

Related subtypes (1): unilateral aplasia of the mullerian ducts

Subtypes (2): mullerian aplasia and hyperandrogenism, Mayer-Rokitansky-Kuster-Hauser syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.